TheAnswerPage

JULY 17, 2022

In 2017, researchers performed an analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Their findings included the following: “The average daily dose ranged between 1 and 50 mg/kg, with treatment length from 3 to 12 months (mean 6.2 12 September 2018.

Epilepsy 56

Epilepsy Extraction Treatment CBD 56

TheAnswerPage

FEBRUARY 14, 2022

One must read the entire answer to be fully informed… As of January 2022, there was one clinical study that showed CBD was well tolerated and reduced acne lesions. This study was a single-arm phase I safety study in 20 healthy volunteers, where a patented 5% CBD formulation (synthetically produced CBD-BTX 1503) was used.

Safety 45

Safety Topical CBD Treatment 45

TheAnswerPage

JUNE 12, 2022

Has the use of a transdermal gel for regional and systemic delivery of CBD been evaluated for the treatment of epilepsy? A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis.

Epilepsy 40

Epilepsy Topical Safety Treatment 40

Veriheal

NOVEMBER 21, 2023

As we reflect on the success of the 2022 recipients, we are thrilled to introduce the exceptional winners of the 2023 scholarship. To alleviate this burden, we awarded $5,000 scholarships to five outstanding individuals in 2022. Veriheal recognizes the financial challenges students face in pursuing higher education.

Research and Development 110

Research and Development Consumption Education Data 110

Veriheal

JANUARY 24, 2023

With its abundance of medicinal properties and non-addictive nature, why does marijuana remain an untapped resource for researchers wanting to find treatments for debilitating chronic diseases like Parkinson’s? Do not attempt to self-diagnose or prescribe treatment based on the information provided. So what gives?

DEA 98

DEA Treatment Medicine Pets 98

The Cannigma

FEBRUARY 1, 2023

7 The use of cannabis as a cancer treatment was popularized by Rick Simpson, a medical cannabis advocate. While RSO has been subject to increased popularity in treating certain types of cancers, no clinical trials have tested the safety or efficacy of RSO in humans, meaning that all evidence is anecdotal. Can cannabis fill this void?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

TheAnswerPage

JULY 2, 2022

” … “Safety and effectiveness of nalmefene hydrochloride injection in pediatric patients have NOT been established.” for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids. for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids. June 21, 2022.

Treatment 40

Treatment Safety Patients Cannabis 40

Veriheal

AUGUST 16, 2023

In an unprecedented move that embraces the evolving landscape of sports health and wellness, the National Football League (NFL) has recently made a significant investment in cannabidiol (CBD) research, aiming to explore its potential as a pain treatment alternative for players suffering from concussions.

CBD 98

CBD Research and Development Treatment Policy 98

The Blunt Truth

JANUARY 5, 2022

Although provisions relating to possession are effective now, the employment-related provisions are not effective until July 1, 2022. Many states are considering enacting new or amending existing laws to provide employment protections to marijuana users, which could result in 2022 also being another busy year in this area.

Law 105

Law Marijuana Policy Recreational 105

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). These adverse events were similar the adverse events in the trials examining the efficacy of CBD for the treatment of seizures. Fletcher S. Child: care, health and development.

Clinical Trials 40

Clinical Trials Events Therapy Sleep 40

Veriheal

JUNE 1, 2023

It had passed through the Senate and the Public Safety and Health committees, but the Assembly Appropriations Committee gutted its main provisions. SB 58, on the other hand, needed to pass through only the Public Safety and Health Committee, hence its accelerated progression to the floor. because there is no public hearing.”

Legalization 96

Legalization Decriminalization Legislation Therapy 96

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. ” The spokesperson added, “Those are the sole motivations for the design of the initiative.

Legalization 111

Legalization Decriminalization Medicine Research and Development 111

TheAnswerPage

MARCH 29, 2022

The primary efficacy outcome is a change in opioid maintenance dose from baseline to the end of the treatment period. Safety and tolerability of CBD will also be assessed throughout the trial. The trial is being conducted at NYU Grossman School of Medicine.

Clinical Trials 40

Clinical Trials Safety Medicine Treatment 40

Cannabis Law Report

MAY 16, 2022

MAY 16, 2022 BY DEANNA J. Gavin Newsom introduced proposed revisions to his 2022-2023 budget proposal, which would eliminate the cannabis cultivation tax rate beginning July 1, 2022. To go into effect, the proposal must be approved by a two-thirds majority of the state legislature by June 15, 2022. Source: [link].

Legalization 52

Legalization Collective Education Cultivation 52

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The document also addresses study participant safety emphasizing how psychedelics’ psychoactive effects increase the potential for abuse.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 18, 2021

Effective January 1, 2022, Philadelphia will join New York City in prohibiting employers, labor organizations, and employment agencies, and all of their agents, from requiring job applicants to submit to a marijuana drug test as a condition of employment, making such a drug test an “unlawful employment practice.” Philadelphia, PA.

Legislation 105

Legislation Legalization Marijuana Recreational 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

TheAnswerPage

JULY 21, 2022

” Busse J W, Vankrunkelsven P, Zeng L, Heen A F, Merglen A, Campbell F et al.

Chronic Pain 40

Chronic Pain Research and Development Cannabinoids Safety 40

Cannabis Law Report

APRIL 14, 2022

Similar issues arise under state and federal employee safety and worker Right-to-Know laws, as employees must be educated on the chemicals present and proper handling and risk management procedures. Since growing cannabis has not always been legal, growers did not always choose pesticides that were “approvable” by EPA.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

JANUARY 13, 2022

.” Newsom’s budget projects that the state will collect $787 million in cannabis revenue during the 2022-23 tax year. Of that, the budget estimates that nearly $595 million will be available to be allocated to youth substance abuse treatment, clean-up of illicit cannabis grows and support public safety-related activities.

Collective 52

Collective Policy Safety Treatment 52

Veriheal

DECEMBER 23, 2022

As a direct effect of cannabis’ federally illegal status, states that have enacted legalization are continuously scampering to find a way of amplifying safety procedures for the marijuana being sold inside their borders. . Department of Agriculture (USDA) applies to other legal consumer products. 74 solvents. 21 microbes.

Research and Development 96

Research and Development Agriculture Data Extraction 96

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

MAY 26, 2022

ICPR 2022 will showcase the latest findings in psychedelic science, novel approaches in psychedelic therapy, and feature developments in policy, consciousness research, neuroscience, philosophy, and much more. Psychedelics have never been hotter,” said Joost Breeksema, the executive director of OPEN Foundation and the organiser of ICPR 2022.

Research and Development 52

Research and Development Therapy Policy Media 52

Cannabis Law Report

FEBRUARY 26, 2022

The organization has, they say, ……evaluated patient access, affordability, equity, and product safety. The analysis explores barriers to access, civil protections, affordability, health and social equity, and product safety, as well as penalties for detrimental policies. POSTED BY ANDREW COON ON FEBRUARY 22, 2022.

Access 98

Access Law Patients Programs 98

Cannabis Law Report

MAY 18, 2022

THE FIRST-EVER MEDICAL PSYCHEDELICS SERIES AT DAVOS 2022 hosted by Energia Holdings Incorporated. Thu, 19 May 2022, 3:23 am · 5-min read. A recent publication in the prominent peer-reviewed journal Nature, shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”).

Research and Development 52

Research and Development Therapy Treatment Policy 52

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D. Christine Lawson. How are CBD and other hemp-containing pet products being marketed today?

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

NOVEMBER 4, 2021

The Oregon Psilocybin Advisory Board (Advisory Board) held a meeting on October 27 to begin fine tuning recommendations for the first regulated psilocybin treatment model in the United States. OHA will work off these recommendations when they hold rule making hearings on products and training from February 14 to 25, 2022.

Law 52

Law Therapy Treatment Policy 52

Cannabis Law Report

MAY 6, 2022

On May 4, 2022, the FDA issued five warning letters to companies for selling products containing hemp-derived Delta-8 THC. Previously, the agency issued and updated a consumer advisory outlining consumer safety concerns relating to Delta-8 products. “[D]elta-8-THC was administered to eight children being treated for hematologic cancers.

Hemp 52

Hemp Food Safety THC 52

Cannabis Law Report

OCTOBER 9, 2021

Session of 2021 – 2022 Regular Session. As traditional treatment has proven inadequate at both the individual and public health level, the Commonwealth has a responsibility to research alternative options. Read more at Marijuana Moment. GOP Pennsylvania Lawmaker Files Psilocybin Research Bill For Veterans And First Responders.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

AUGUST 23, 2022

Mora on August 22, 2022. Last month, on July 13, 2022, Washington, D.C. Mayor Muriel Bowser signed the “ Cannabis Employment Protections Amendment Act of 2022 ” (D.C. By Jennifer L. Act 24-483), joining the growing list of jurisdictions prohibiting most employers from taking adverse action (e.g.,

Safety 52

Safety Environment Policy Recreational 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time. Dr. Nick Allen, co-founder and CEO of Ksana Health, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

United Patients Group

JANUARY 24, 2023

Potential patients and recommending medical professionals, on the other hand, have questions about the efficacy, safety, accessibility, and other features of cannabis, but they are unsure where to find the answers. These treatments are used to treat a variety of medical conditions. Several sites are undergoing transformation.

Marijuana 52

Marijuana Wellness and Beauty Patients Cannabinoids 52

Cannabis Law Report

FEBRUARY 9, 2022

09, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. This is important because, as a psychedelic, ketamine is a stunningly effective treatment for many mental health disorders. However, some Americans are not clear on its legality, safety and effectiveness. LOS ANGELES, Feb.

Access 52

Access Patients Safety Treatment 52

Cannabis Law Report

SEPTEMBER 17, 2022

At a hearing before the City Council Public Safety & Legal Administration Committee, members took public comment on the measure that was recently filed Councilmember Liliana Bakhtiari. Sep 12, 2022 1:00 PM. Sep 6, 2022 1:00 PM Video. REFERRED TO PUBLIC SAFETY AND LEGAL ADMINISTRATION COMMITTEE WITHOUT OBJECTION.

Treatment 52

Treatment Safety Decriminalization Conditions 52

Cannabis Law Report

JUNE 26, 2022

Beginning July 1, 2022, Connecticut’s law legalizing the recreational use of cannabis for adults 21 and over imposes new restrictions on employers while offering protections for employees who indulge. New Employee Protections for Off-Duty and Non-Work Cannabis Use. Updating Employment Handbooks and Policies.

Recreational 52

Recreational Policy Legalization Safety 52

Cannabis Law Report

SEPTEMBER 6, 2022

Russo on September 6, 2022. Department of Transportation, Federal Motor Carrier Safety Administration (FMCSA) published a proposed draft Medical Examiner’s Handbook (MEH), including updates to the Medical Advisory Criteria, in the Federal Register on August 16, 2022. By Kathryn J. The draft MEH may be viewed here.

CBD 52

CBD THC Treatment History 52

Cannabis Law Report

JULY 21, 2022

On July 13, 2022, Washington, D.C., In such circumstances, the law appears to allow employees with disabilities to use cannabis at work in a non-smokable form so long as: (1) the employee is not in a safety-sensitive position, and (2) the employer is not committing a violation of federal statute, regulation, contract or funding agreement.

Recreational 52

Recreational Safety Programs Law 52